4B99

Crystal Structure of MAPK7 (ERK5) with inhibitor

Summary for 4B99

• Entry DOI: 10.2210/pdb4b99/pdb
• Descriptor: MITOGEN-ACTIVATED PROTEIN KINASE 7, 11-cyclopentyl-2-[[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl-phenyl]amino]-5-methyl-pyrimido[4,5-b][1,4]benzodiazepin-6-one (3 entities in total)
• Functional Keywords: transferase, inhibitor
• Biological source: HOMO SAPIENS (HUMAN)
• Cellular location: Cytoplasm: Q13164
• Total number of polymer chains: 1
• Total formula weight: 45628.37

Authors

Elkins, J.M.,Wang, J.,Vollmar, M.,Mahajan, P.,Savitsky, P.,Deng, X.,Gray, N.S.,Pike, A.C.W.,von Delft, F.,Bountra, C.,Arrowsmith, C.,Edwards, A.,Knapp, S. (deposition date: 2012-09-03, release date: 2012-09-19, Last modification date: 2023-12-20)

Primary citation

Elkins, J.M.,Wang, J.,Deng, X.,Pattison, M.J.,Arthur, S.,Erazo, T.,Gomez, N.,Lizcano, J.M.,Gray, N.S.,Knapp, S.
X-Ray Crystal Structure of Erk5 (Mapk7) in Complex with a Specific Inhibitor.
J.Med.Chem., 56:4413-, 2013

PubMed Abstract: The protein kinase ERK5 (MAPK7) is an emerging drug target for a variety of indications, in particular for cancer where it plays a key role mediating cell proliferation, survival, epithelial-mesenchymal transition, and angiogenesis. To date, no three-dimensional structure has been published that would allow rational design of inhibitors. To address this, we determined the X-ray crystal structure of the human ERK5 kinase domain in complex with a highly specific benzo[e]pyrimido[5,4-b]diazepine-6(11H)-one inhibitor. The structure reveals that specific residue differences in the ATP-binding site, compared to the related ERKs p38s and JNKs, allow for the development of ERK5-specific inhibitors. The selectivity of previously observed ERK5 inhibitors can also be rationalized using this structure, which provides a template for future development of inhibitors with potential for treatment of disease.

PubMed: 23656407
DOI: 10.1021/JM4000837

Experimental method

X-RAY DIFFRACTION (2.8 Å)